This Medical Pot Stock Is Not What You Think It Is

And there’s risk that the company won’t get Sativex approved or that it won’t sell well if clinical trials show that it’s not better than generic pain medications. I like the risk-reward situation here, at a market cap under $700 million, than I did when the company was over $1.2 billion, but only for an investor that’s willing to hold for multiple years.

In this biotech market, it’s hard to say whether GW Pharmaceuticals has hit bottom, especially since it’s trading considerably higher than it was a year ago. Investors may need to wait until one of the other pipeline drugs is approved before GW Pharmaceuticals reaches its full potential. Look beyond medical marijuana (and don’t let your portfolio go up in smoke) They said it couldn’t be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he’s ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he’s making this premium report free for you today.

To read more, visit http://www.fool.com/investing/general/2014/04/19/this-medical-marijuana-stock-is-not-what-you-think.aspx

Comments are closed.

PLEASE SUBSCRIBE
Get the latest content first.
©Marijuana Stocks Report